ABSTRACT
BACKGROUND: PCSK9 (Proprotein convertase subtilisin/kexin type 9) regulates LDL-C (low-density lipoprotein cholesterol) metabolism by targeting LDLr (LDL receptor) for lysosomal degradation. PCSK9 gain-of-function variants cause autosomal dominant hypercholesterolemia by reducing LDLr levels, the D374Y variant being the most severe, while loss-of-function variants are associated with low LDL-C levels. Gain-of-function and loss-of-function activities have also been attributed to variants occurring in the PCSK9 signal peptide. Among them, L11 is a very rare PCSK9 variant that seems to increase LDL-C values in a moderate way causing mild hypercholesterolemia. METHODS: Using molecular biology and biophysics methodologies, activities of L8 and L11 variants, both located in the leucine repetition stretch of the signal peptide, have been extensively characterized in vitro. RESULTS: L8 variant is not associated with increased LDLr activity, whereas L11 activity is increased by ≈20% compared with wt PCSK9. The results suggest that the L11 variant reduces LDLr levels intracellularly by a process resulting from impaired cleavage of the signal peptide. This would lead to less efficient LDLr transport to the cell membrane and promote LDLr intracellular degradation. CONCLUSIONS: Deletion of a leucine in the signal peptide in L8 variant does not affect PCSK9 activity, whereas the leucine duplication in the L11 variant enhances LDLr intracellular degradation. These findings highlight the importance of deep in vitro characterization of PCSK9 genetic variants to determine pathogenicity and improve clinical diagnosis and therapy of inherited familial hypercholesterolemia disease.
Subject(s)
Hyperlipoproteinemia Type II , Proprotein Convertase 9 , Cholesterol, LDL , Humans , Hyperlipoproteinemia Type II/diagnosis , Hyperlipoproteinemia Type II/genetics , Leucine , Proprotein Convertase 9/genetics , Proprotein Convertase 9/metabolism , Protein Sorting Signals , Receptors, LDL/genetics , Receptors, LDL/metabolismABSTRACT
Genetic laboratories use custom-commercial targeted next-generation sequencing (tg-NGS) assays to identify disease-causing variants. Although the high coverage achieved with these tests allows for the detection of copy number variants (CNVs), which account for an important proportion of the genetic burden in human diseases, an easy-to-use tool for automatic CNV detection is still lacking. This article presents a new CNV detection tool optimized for tg-NGS data: PattRec. PattRec was evaluated using a wide range of data, and its performance compared with those of other CNV detection tools. The software includes features for selecting optimal controls, discarding polymorphic CNVs prior to analysis, and filtering out deletions based on SNV zygosity, and automatically creates an in-house CNV database. There is no need for high level bioinformatic expertise and users can choose color-coded xlsx output that helps to prioritize potentially pathogenic CNVs. PattRec is presented as a Java based GUI, freely available online: https://github.com/irotero/PattRec.
Subject(s)
DNA Copy Number Variations , Genetic Testing/methods , High-Throughput Nucleotide Sequencing/methods , Sequence Analysis, DNA/methods , Software , HumansABSTRACT
Familial hypercholesterolemia (FH) is an autosomal-dominant disorder mostly caused by mutations in the low-density lipoprotein receptor (LDLR) gene leading to increased risk for premature cardiovascular diseases. According to functional studies, LDLR mutations may be classified into five classes. The main objective of this study was to characterize seven LDLR variants previously detected in FH patients. Analysis by flow cytometry and confocal microscopy of LDLR activity demonstrate that all the studied variants are pathogenic. Among the mutations located in ß-propeller, p.Trp577Gly and p.Ile624del were classified as class 2, whereas p.Arg416Trp and p.Thr454Asn as class 5. p.Phe800Glyfs*129 (located in the cytoplasmic domain), p.Cys155Tyr (located in the binding domain), and p.Asn825Lys (inside FxNPxY motif) were classified as class 2, 3, and 4, respectively. The results also show that LDLR activity of these class 4 and 5 variants is not completely abolished, showing a milder phenotype. We have also determined that statin response is more efficient lowering total cholesterol in heterozygous patients carrying p.Ile624del (class 2) compared with p.Arg416Trp and p.Thr454Asn (class 5) variants. In conclusion, these findings emphasize the importance of characterizing LDLR pathogenic variants to provide an indisputable FH diagnosis and to gain insight into the statin response depending on the LDLR class mutation.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/drug therapy , Hyperlipoproteinemia Type II/genetics , Hypolipidemic Agents/therapeutic use , Receptors, LDL/chemistry , Receptors, LDL/genetics , Adult , Animals , CHO Cells , Cricetulus , Humans , Middle Aged , Polymorphism, Single Nucleotide , Protein Structure, Tertiary , Receptors, LDL/metabolismABSTRACT
Familial hypercholesterolemia (FH) is an autosomal dominant disorder mostly caused by mutations in the LDLR gene. Although the detection of functional mutations in the LDLR gene provides an unequivocal diagnosis of the FH condition, there are many variants whose pathogenicity is still unknown. The aims of this study were to set up a rapid method to determine the effect of LDLR mutations, thereby providing an accurate diagnosis of FH, and to functionally characterize six LDLR mutations detected at high frequency by the LIPOchip(®) platform (Progenika Biopharma, Spain) in the Spanish population. LDLR expression and activity were analyzed by one-single-step flow cytometry assay and confocal microscopy. Splicing effects were determined by sequencing reverse transcription polymerase chain reaction products. The analysis of three heterozygous variants with a single point mutation within the low-density lipoprotein binding domain allowed us to classify the c.806G>A variant as nonpathogenic, and c.862G>A and c.895G>A variants as causative of FH. The results obtained for three variants affecting donor splice sites of the LDLR mRNA, c.313+2dupT, c.1186+5G>A, and c.1845+1G>C, demonstrated that these mutations are pathogenic. These results expand our knowledge of mutations responsible for FH, providing an accurate diagnosis and leading to early treatment to reduce the risk of premature cardiovascular events.
Subject(s)
Hyperlipoproteinemia Type II/genetics , Lipoproteins, LDL/metabolism , RNA Splicing , Receptors, LDL/genetics , Base Sequence , Binding Sites , Case-Control Studies , Cells, Cultured , DNA Mutational Analysis , Exons , Gene Expression , Heterozygote , Humans , Hyperlipoproteinemia Type II/diagnosis , Hyperlipoproteinemia Type II/metabolism , Molecular Sequence Data , Point Mutation , Protein Binding , Protein Structure, Tertiary , RNA Splice Sites , Receptors, LDL/metabolism , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/metabolismABSTRACT
OBJECTIVE: To determine the association between socioeconomic level and the presence of obesity, hypertension and type 2 diabetes mellitus in the Peruvian population. METHODS: Secondary analysis of data from the National Demographic and Family Health Survey ( Encuesta Nacional Demográfica y de Salud Familiar , Endes) from 2018 to 2020. The outcomes were obesity, hypertension, and type 2 diabetes mellitus. The exposure variables were two indicators of socioeconomic status: educational level (< 7 years, 7-11 years, and 12+ years) and wealth index (in tertiles). Models were created using Poisson regression, reporting prevalence ratios (PR) and 95% confidence intervals (95%CI). RESULTS: Data from 98,846 subjects were analyzed. Mean age: 45.3 (SD: 16.0) years, and 55.5% were women. The prevalence of obesity was 26.0% (95%CI: 25.4-26.6); of hypertension, 24.9% (95%CI: 24.3-25.5); and of type 2 diabetes mellitus, 4.8% (95%CI: 4.5-5.1). In multivariate model, and compared with those with a low wealth index, those with a high wealth index had a higher prevalence of obesity (PR = 1.49; 95%CI: 1.38-1.62), hypertension (PR = 1.09; 95%CI: 1.02-1.17) and type 2 diabetes mellitus (PR = 1.72; 95%CI: 1.29-2.29). On the other hand, higher educational level was only associated with a reduction in the prevalence of obesity (PR = 0.89; 95%CI: 0.84-0.95). CONCLUSIONS: There is a differential association between the wealth index, educational level and markers of noncommunicable diseases. There is evidence of a positive association between wealth index and obesity, hypertension and type 2 diabetes mellitus, whereas educational level was only negatively associated with obesity.
Subject(s)
Cardiovascular Diseases , Diabetes Mellitus, Type 2 , Hypertension , Female , Humans , Middle Aged , Male , Diabetes Mellitus, Type 2/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Risk Factors , Peru/epidemiology , Cross-Sectional Studies , Brazil/epidemiology , Obesity/epidemiology , Hypertension/epidemiology , Social Class , Heart Disease Risk Factors , Prevalence , Socioeconomic FactorsABSTRACT
Testing is crucial in controlling COVID-19. The Procleix® SARS-CoV-2 assay, a transcription-mediated amplification nucleic acid test that runs on an automated system, was evaluated using inactivated virus and clinical samples. The sensitivity of the assay was assessed using heat-inactivated SARS-CoV-2 and compared to 3 other tests. Clinical validation utilized 2 sets of samples: (1) Nasal, nasopharyngeal and oropharyngeal samples (n = 963) from asymptomatic individuals, and (2) nasopharyngeal samples from symptomatic patients: 100 positive and 100 negative by RT-PCR. The Procleix assay had greater sensitivity (3-fold to 100-fold) than the comparators and had high specificity (100%) in asymptomatic subjects. In symptomatic patients, the Procleix assay detected 100% of PCR-positives and found 24 positives in the initial PCR-negatives. Eighteen of these were confirmed positive and 6 were inconclusive. These studies showed that the Procleix SARS-CoV-2 assay was a sensitive and specific tool for detecting COVID-19.
Subject(s)
Automation , COVID-19 Testing/methods , COVID-19/diagnosis , COVID-19/virology , SARS-CoV-2/isolation & purification , High-Throughput Screening Assays , Humans , Molecular Diagnostic Techniques , Nucleic Acid Amplification Techniques , Retrospective Studies , Sensitivity and SpecificityABSTRACT
Familial hypercholesterolemia (FH) is a dominant disorder due to mutations in the LDLR gene. Several mutations in the LDLR promoter are associated with FH. Screening of 3,705 Spanish FH patients identified 10 variants in the promoter and 5' UTR. Here, we analyse the functionality of six newly identified LDLR variants. Mutations located in the LDLR promoter regulatory elements R2 and R3 (c.-155_-150delACCCCinsTTCTGCAAACTCCTCCC, c.-136C>G, c.-140C>G, and c.-140C>T) resulted in 6 to 15% residual activity in reporter expression experiments and changes in nuclear protein binding affinity compared to wild type. No reduction was observed when cells were transfected with c.-208T, c.-88A, and c.-36G mutant fragments. Our results indicate that mutations localized in R2 and R3 are associated with hypercholesterolemia, whereas mutations outside the LDLR response elements are not a cause of FH. This data emphasizes the importance of functional analysis of variants in the LDLR promoter to determine their association with the FH phenotype.
Subject(s)
5' Untranslated Regions/genetics , Hyperlipoproteinemia Type II/genetics , Mutation/genetics , Promoter Regions, Genetic/genetics , Receptors, LDL/genetics , Base Sequence , Cell Line, Tumor , Consensus Sequence/genetics , Electrophoretic Mobility Shift Assay , Hep G2 Cells , Humans , Molecular Sequence DataABSTRACT
Variations in the gene encoding the low-density lipoprotein receptor (LDLR) can cause familial hypercholesterolemia (FH), one of the most common inherited metabolic disorders in humans. The functional effects of the p.Gln92Glu and p.Asn564His alterations are predicted as benign, but the c.313 + 1G>C and p.Lys799_Phe801del changes are believed to cause disease. Although p.Gln92Glu and c.313 + 1G>C have been observed only in Spain, p.Asn564His and p.Lys799_Phe801del are widespread in Western Europe. In order to estimate the ages (t generations) of these four variants of the gene, to determine their possible origin and to consider the influence of age and selective pressure on their spread, we analyzed 86 healthy individuals and 126 FH patients in Spain. Most of the FH patients investigated carried two of these four LDLR variants simultaneously, while only one patient carried three of them simultaneously. Haplotype analyses were based on five LDLR SNPs: c.81T>C, c.1413G>A, c.1725C>T, c.1959T>C and c.2232G>A. The results suggest that p.Gln92Glu and c.313 + 1G>C arose at about the same time (99 and 103 generations ago, respectively) in the CACTG haplotype and that p.Asn564His and p.Lys799_Phe801del appeared in the CGCCG haplotype and might be slightly more recent variations (92 and 95 generations ago, respectively). Low selective pressures could explain the maintenance of these variants in spite of their ages. The origin of p.Gln92Glu and c.313 + 1G>C appears to be in Spain whereas p.Asn564His and p.Lys799_Phe801del could have been introduced in Spain by Celtic migrations in the seventh to fifth centuries BC.
Subject(s)
Mutation , Receptors, LDL/genetics , Case-Control Studies , Haplotypes , Humans , Hyperlipoproteinemia Type II/genetics , Polymorphism, Single Nucleotide , Spain , Time FactorsABSTRACT
INTRODUCTION AND OBJECTIVES: Our objective was to approximate the prevalence of mutations in candidate genes for familial hypercholesterolemia (FH) in a middle-aged Spanish population and to establish the predictive value of criteria for clinical suspicion in the detection of causative mutations. METHODS: Unrelated individuals aged ≥ 18 years from the Aragon Workers' Health Study (AWHS) with high low-density lipoprotein cholesterol (LDL-C) and clinical suspicion of FH (participants with LDL-C concentrations above the 95th percentile, participants with premature cardiovascular disease and/or participants with high LDL-C [130 mg/dL] under statin therapy), assuming that any participant with FH exhibits at leats 1 trait, were selected and the LDLR, APOB, PCSK9, APOE, STAP1 and LDLRAP1 genes were sequenced by next generation sequencing technology. RESULTS: Of 5400 individuals from the AWHS, 4514 had complete data on lipid levels and lipid-lowering drugs, 255 participants (5.65%) met the criteria for suspicion of FH, 24 of them (9.41%) were diagnosed with hyperlipoproteinemia(a), and 16 (6.27% of those sequenced) were found to carry causative mutations in candidate genes: 12 participants carried 11 different pathogenic LDLR alleles and 4 participants carried 1 pathogenic mutation in PCSK9. LDL-C concentrations> 220 mg/dL and LDL-C> 130 mg/dL despite statin therapy showed the strongest association with the presence of mutations (P=.011). CONCLUSIONS: Our results show that the prevalence of FH in Spain is 1:282 and suggest that the combination of high untreated LDL-C and high levels of LDL-C despite statin therapy are the best predictors of a positive FH genetic test.
Subject(s)
Hypercholesterolemia , Hyperlipoproteinemia Type II , Humans , Hypercholesterolemia/diagnosis , Hypercholesterolemia/epidemiology , Hypercholesterolemia/genetics , Hyperlipoproteinemia Type II/diagnosis , Hyperlipoproteinemia Type II/epidemiology , Hyperlipoproteinemia Type II/genetics , Middle Aged , Mutation , Proprotein Convertase 9/genetics , Spain/epidemiologyABSTRACT
The primary genetic cause of familial hypercholesterolemia (FH) is related to mutations in the LDLR gene encoding the Low-density Lipoprotein Receptor. LDLR structure is organized in 5 different domains, including an EGF-precursor homology domain that plays a pivotal role in lipoprotein release and receptor recycling. Mutations in this domain constitute 51.7% of the total missense variants described in LDLR. The aim of the present work was to analyse how clinically significant variants in the EGF-precursor homology domain impact LDLR. The activity of sixteen LDLR variants was functionally characterized by determining LDLR expression by Western blot and LDLR expression, LDL binding capacity and uptake, and LDLR recycling activity by flow cytometry in transfected CHO-ldlA7 cells. Of the analysed variants, we found six non-pathogenic LDLR variants and ten pathogenic variants distributed as follow: three class 3 variants; four class 2 variants; and three class 5 variants. These results can be incorporated into clinical management of patients by helping guide the appropriate level of treatment intensity depending on the extent of loss of LDLR activity. This data can also contribute to cascade-screening for pathogenic FH variants.
Subject(s)
Hyperlipoproteinemia Type II/genetics , Mutation, Missense/genetics , Receptors, LDL/genetics , Animals , CHO Cells , Cricetulus , Epidermal Growth Factor/genetics , Humans , Lipoproteins, LDL/metabolism , Phenotype , Polymorphism, Genetic , Protein Domains/genetics , Receptors, LDL/metabolismABSTRACT
Identifying immune correlates of protection and mechanisms of immunity accelerates and streamlines the development of vaccines. RTS,S/AS01E, the most clinically advanced malaria vaccine, has moderate efficacy in African children. In contrast, immunization with sporozoites under antimalarial chemoprophylaxis (CPS immunization) can provide 100% sterile protection in naïve adults. We used systems biology approaches to identifying correlates of vaccine-induced immunity based on transcriptomes of peripheral blood mononuclear cells from individuals immunized with RTS,S/AS01E or chemoattenuated sporozoites stimulated with parasite antigens in vitro. Specifically, we used samples of individuals from two age cohorts and three African countries participating in an RTS,S/AS01E pediatric phase 3 trial and malaria-naïve individuals participating in a CPS trial. We identified both preimmunization and postimmunization transcriptomic signatures correlating with protection. Signatures were validated in independent children and infants from the RTS,S/AS01E phase 3 trial and individuals from an independent CPS trial with high accuracies (>70%). Transcription modules revealed interferon, NF-κB, Toll-like receptor (TLR), and monocyte-related signatures associated with protection. Preimmunization signatures suggest that priming the immune system before vaccination could potentially improve vaccine immunogenicity and efficacy. Last, signatures of protection could be useful to determine efficacy in clinical trials, accelerating vaccine candidate testing. Nevertheless, signatures should be tested more extensively across multiple cohorts and trials to demonstrate their universal predictive capacity.
Subject(s)
Malaria Vaccines , Malaria, Falciparum , Malaria , Adult , Africa , Antibodies, Protozoan , Child , Humans , Immunization , Infant , Leukocytes, Mononuclear , Malaria/prevention & control , Malaria, Falciparum/prevention & control , Plasmodium falciparumABSTRACT
SND p102 belongs to an evolutionarily conserved family of proteins first described as transcriptional coactivators, whose biological function has not yet been defined. High expression levels of homologues of SND p102 in non-nuclear compartments of lipid secretory tissues and in murine liver endoplasmic reticulum suggest a role for SND p102 in lipoprotein secretion in hepatocytes. To address this issue, after ascribing by confocal microscopy and Western blotting a non-nuclear localization of SND p102 in rat hepatocytes, we cloned its full-length cDNA, developed adenoviral vectors encoding the cDNA or a specific antisense sequence, and characterized the lipoprotein particles created and released for 24 h by transfected rat hepatocytes. The cellular ability to secrete apoB and apoA-I was not affected by SND p102 differential expression, nor was that of lipoproteins-triglyceride, -cholesterol and -cholesteryl esters. However, cells overexpressing SND p102 secreted phospholipid-rich lipoproteins. Compared with hepatocytes with basal or attenuated SND p102 expression, they secreted approximately 45% and 80% more phospholipid in d<1.015 g/mL and 1.015Subject(s)
Hepatocytes/metabolism
, Nuclear Proteins
, Phospholipids/metabolism
, Animals
, Cells, Cultured
, Cloning, Molecular
, DNA, Complementary/genetics
, DNA, Complementary/isolation & purification
, Endonucleases
, Female
, Gene Expression
, Humans
, Lipoproteins, VLDL/chemistry
, Lipoproteins, VLDL/metabolism
, Nuclear Proteins/biosynthesis
, Nuclear Proteins/genetics
, Rats
, Rats, Sprague-Dawley
, Trans-Activators/biosynthesis
, Trans-Activators/genetics
ABSTRACT
ABSTRACT OBJECTIVE To determine the association between socioeconomic level and the presence of obesity, hypertension and type 2 diabetes mellitus in the Peruvian population. METHODS Secondary analysis of data from the National Demographic and Family Health Survey ( Encuesta Nacional Demográfica y de Salud Familiar , Endes) from 2018 to 2020. The outcomes were obesity, hypertension, and type 2 diabetes mellitus. The exposure variables were two indicators of socioeconomic status: educational level (< 7 years, 7-11 years, and 12+ years) and wealth index (in tertiles). Models were created using Poisson regression, reporting prevalence ratios (PR) and 95% confidence intervals (95%CI). RESULTS Data from 98,846 subjects were analyzed. Mean age: 45.3 (SD: 16.0) years, and 55.5% were women. The prevalence of obesity was 26.0% (95%CI: 25.4-26.6); of hypertension, 24.9% (95%CI: 24.3-25.5); and of type 2 diabetes mellitus, 4.8% (95%CI: 4.5-5.1). In multivariate model, and compared with those with a low wealth index, those with a high wealth index had a higher prevalence of obesity (PR = 1.49; 95%CI: 1.38-1.62), hypertension (PR = 1.09; 95%CI: 1.02-1.17) and type 2 diabetes mellitus (PR = 1.72; 95%CI: 1.29-2.29). On the other hand, higher educational level was only associated with a reduction in the prevalence of obesity (PR = 0.89; 95%CI: 0.84-0.95). CONCLUSIONS There is a differential association between the wealth index, educational level and markers of noncommunicable diseases. There is evidence of a positive association between wealth index and obesity, hypertension and type 2 diabetes mellitus, whereas educational level was only negatively associated with obesity.
RESUMEN OBJETIVO Determinar la asociación entre el nivel socioeconómico y la presencia de obesidad, hipertensión y diabetes mellitus tipo 2 en la población peruana. MÉTODOS Análisis de datos secundarios de la Encuesta Nacional Demográfica y de Salud Familiar (Endes) del 2018 al 2020. Las variables dependientes fueron obesidad, hipertensión y diabetes mellitus tipo 2, y las variables independientes fueron dos indicadores de nivel socioeconómico: el nivel educativo (< 7 años, 7-11 años y 12+ años) y el índice de bienestar (en terciles). Se crearon modelos usando regresión de Poisson, reportando razones de prevalencia (RP) e intervalos de confianza al 95% (IC95%). RESULTADOS Se analizaron los datos de 98.846 sujetos, edad promedio: 45,3 (DE: 16,0) años, y 55,5% fueron mujeres. La prevalencia de obesidad fue del 26% (IC95% 25,4-26,6); la de hipertensión, 24,9% (IC95% 24,3-25,5); y la de diabetes mellitus tipo 2, 4,8% (IC95% 4,5-5,1). En modelo multivariable y comparado con los de índice de bienestar bajo, aquellos con índice de bienestar alto tenían mayor prevalencia de obesidad (RP = 1,49; IC95% 1,38-1,62), de hipertensión (RP = 1,09; IC95% 1,02-1,17) y de diabetes mellitus tipo 2 (RP = 1,72; IC95% 1,29-2,29). De otro lado, mayor nivel educativo sólo se asoció a una reducción en la prevalencia de obesidad (RP = 0,89; IC95% 0,84-0,95). CONCLUSIONES Existe asociación diferencial entre el índice de bienestar, nivel educativo y marcadores de enfermedades no transmisibles: hay evidencia de asociación positiva entre el índice de bienestar y obesidad, hipertensión y diabetes mellitus tipo 2, mientras que el nivel educativo solo estuvo asociado de forma negativa a obesidad.
Subject(s)
Humans , Male , Female , Middle Aged , Peru/epidemiology , Socioeconomic Factors , Chronic Disease/epidemiology , Risk Factors , Heart Disease Risk FactorsABSTRACT
We report the case of a newborn with arthrogryposis multiplex congenita and severe axial hypotonia without cardiac involvement in which, using a customized targeted next-generation sequencing assay for 64 myopathy-associated genes, we detected a novel homozygous truncating mutation, c.38661_38665del, in exon 197 of the TTN gene that is expressed only in the fetal skeletal isoform. Its pathogenicity is supported by evidence of maternal isodisomy for chromosome 2. Muscle pathology showed fibers with core-like areas devoid of oxidative staining and cytoplasmic bodies. Electron microscopy showed the replacement of the sarcomeric structure with filamentous material. Identification of this mutation expands the phenotypic spectrum of the TTN gene and shows for the first time that a mutation not found in adult TTN isoforms is involved in the development of a neuromuscular disorder. TTN mutations should be considered in all severe congenital myopathies with arthrogryposis without cardiac involvement.
Subject(s)
Arthrogryposis/genetics , Connectin/genetics , Muscular Diseases/genetics , Humans , Infant, Newborn , Muscular Diseases/congenital , Mutation , Protein IsoformsABSTRACT
CONTEXT: The p.Leu167del mutation in the APOE gene has been associated with hyperlipidemia. OBJECTIVES: Our objective was to determine the frequency of p.Leu167del mutation in APOE gene in subjects with autosomal dominant hypercholesterolemia (ADH) in whom LDLR, APOB, and PCSK9 mutations had been excluded and to identify the mechanisms by which this mutant apo E causes hypercholesterolemia. DESIGN: The APOE gene was analyzed in a case-control study. SETTING: The study was conducted at a University Hospital Lipid Clinic. PATIENTS OR OTHER PARTICIPANTS: Two groups (ADH, 288 patients; control, 220 normolipidemic subjects) were included. INTERVENTION: We performed sequencing of APOE gene and proteomic and cellular experiments. MAIN OUTCOME MEASURE: To determine the frequency of the p.Leu167del mutation and the mechanism by which it causes hypercholesterolemia. RESULTS: In the ADH group, nine subjects (3.1%) were carriers of the APOE c.500_502delTCC, p.Leu167del mutation, cosegregating with hypercholesterolemia in studied families. Proteomic quantification of wild-type and mutant apo E in very low-density lipoprotein (VLDL) from carrier subjects revealed that apo E3 is almost a 5-fold increase compared to mutant apo E. Cultured cell studies revealed that VLDL from mutation carriers had a significantly higher uptake by HepG2 and THP-1 cells compared to VLDL from subjects with E3/E3 or E2/E2 genotypes. Transcriptional down-regulation of LDLR was also confirmed. CONCLUSIONS: p.Leu167del mutation in APOE gene is the cause of hypercholesterolemia in the 3.1% of our ADH subjects without LDLR, APOB, and PCSK9 mutations. The mechanism by which this mutation is associated to ADH is that VLDL carrying the mutant apo E produces LDLR down-regulation, thereby raising plasma low-density lipoprotein cholesterol levels.
Subject(s)
Apolipoproteins E/genetics , Down-Regulation/genetics , Hepatocytes/metabolism , Hyperlipoproteinemia Type II/genetics , Mutation , Receptors, LDL/genetics , Adult , Apolipoproteins E/metabolism , Case-Control Studies , DNA Mutational Analysis , Female , Humans , Hyperlipoproteinemia Type II/metabolism , Male , Middle Aged , Receptors, LDL/metabolismABSTRACT
BACKGROUND: Mitochondrial diseases due to deficiencies in the mitochondrial oxidative phosphorylation system (OXPHOS) can be associated with nuclear genes involved in mitochondrial translation, causing heterogeneous early onset and often fatal phenotypes. CASE REPORT: The authors describe the clinical features and diagnostic workup of an infant who presented with an early onset severe encephalopathy, spastic-dystonic tetraparesis, failure to thrive, seizures and persistent lactic acidemia. Brain imaging revealed thinning of the corpus callosum and diffuse alteration of white matter signal. Genetic investigation confirmed two novel mutations in the GFM1 gene, encoding the mitochondrial translation elongation factor G1 (mtEFG1), resulting in combined deficiencies of OXPHOS. DISCUSSION: The patient shares multiple clinical, laboratory and radiological similarities with the 11 reported patients with mutations involving this gene, but presents with a stable clinical course without metabolic decompensations, rather than a rapidly progressive fatal course. Defects in GFM1 gene confer high susceptibility to neurologic or hepatic dysfunction and this is, to the best of our knowledge, the first described patient who has survived beyond early childhood. Reporting of such cases is essential so as to delineate the key clinical and neuroradiological features of this disease and provide a more comprehensive view of its prognosis.
ABSTRACT
[This corrects the article on p. 102 in vol. 6, PMID: 25852744.].
ABSTRACT
In the context of a study of the involvement of SND1 (also known as coactivator p100) in biliary lipid secretion by primary rat hepatocytes, first-generation adenoviral vectors were used to promote the overexpression and underexpression of the protein SND1. Although differential expression of SND1 did not result in significant changes in the processes studied, some effects of the adenoviral infection itself were observed. In particular, infected hepatocytes showed a higher intracellular taurocholate accumulation capacity. Additionally, small heterodimer partner (SHP) and farnesoid X receptor (FXR), which are nuclear receptors essential for the regulation of bile salt metabolism and transport, were underregulated at the mRNA level. Our results suggest that adenoviral vectors could be altering some important control mechanism and indicate that adenoviral vectors should be used with caution as transfection vectors for hepatocytes when biliary lipid metabolism is to be studied.
Subject(s)
Adenoviridae/genetics , Bile Acids and Salts/metabolism , Genetic Vectors/genetics , Hepatocytes/virology , Lipid Metabolism , Animals , Antisense Elements (Genetics) , Bile/metabolism , Endonucleases , Hepatocytes/metabolism , Nuclear Proteins/genetics , Nuclear Proteins/physiology , RatsABSTRACT
To facilitate genetic cascade screening for familial hypercholesterolemia (FH) in Europe, two versions (7 and 9) of a DNA microarray were developed to detect the most frequent point mutations in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) genes. The design of these microarrays is based on LIPOchip, version 4, which detects 191 LDLR and APOB mutations identified in Spanish patients with FH. A major improvement of LIPOchip, versions 7 and 9, is the ability to detect copy number variation (deletions or duplications of entire exons) in LDLR, thus abolishing the need to perform multiplex ligase-dependent probe amplification in patients with FH. The aim of this study was to validate a tool capable of detecting point mutations and copy number variations simultaneously and to evaluate its use and the newly developed software for analysis in clinical practice by reanalysis of several patients with known mutations causing FH. With the help of these validations, several aspects were analyzed, improved, and implemented in a newer version, which was evaluated through an internal validation.
Subject(s)
DNA Copy Number Variations , Hyperlipoproteinemia Type II/genetics , Oligonucleotide Array Sequence Analysis/methods , Point Mutation , Receptors, LDL/genetics , Apolipoproteins B/genetics , Europe/epidemiology , Exons , Female , Genetic Testing , Humans , Hyperlipoproteinemia Type II/epidemiology , Male , Proprotein Convertase 9 , Proprotein Convertases/genetics , Reproducibility of Results , Serine Endopeptidases/genetics , Spain/epidemiologyABSTRACT
Familial hypercholesterolemia (FH), characterized by isolated elevation of plasmatic low-density lipoprotein (LDL) cholesterol and premature coronary heart disease (CHD), is associated with mutations in three major genes: LDL receptor (LDLR), apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin 9 (PCSK9). We have analyzed 5430 Spanish index cases and 2223 relatives since 2004 with LIPOchip(®) genetic diagnostic platform, a microarray for the detection of Spanish common mutations in these three genes, including copy number variation (CNV) in LDLR, followed by sequencing analysis of the coding regions of LDLR and exon 26 of APOB, when the result is negative. Samples were received from hospitals of all around Spain. The preferred clinical criterion to diagnose FH was Dutch Lipid Clinic Network (DLCN) score. Our results show that there is a broad spectrum of mutations in the LDLR gene in Spain since about 400 different mutations were detected, distributed along almost the whole LDLR gene. Mutations in APOB (mainly p.Arg3527Gln) covered 6.5% of positive cases and only one PCSK9 mutation was detected. We found correlation between more severe mutations and the clinical diagnosis but also that 28% of FH patients harboring mutations do not have a definite clinical diagnosis. This study analyzes the mutation spectrum in Spain, remarks the importance of genetic diagnosis of FH patients, as well as the cascade screening, and shows how it is being carried out in Spain.